What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Acquired immunodeficiency syndrome
- Disease
His scientific interests lie mostly in Internal medicine, Emtricitabine, Immunology, Efavirenz and Acquired immunodeficiency syndrome.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Lipodystrophy and Endocrinology.
His work carried out in the field of Emtricitabine brings together such families of science as Elvitegravir, Tenofovir alafenamide, Abacavir, Regimen and Cobicistat.
Paul E. Sax focuses mostly in the field of Immunology, narrowing it down to matters related to Pre-exposure prophylaxis and, in some cases, Intensive care medicine.
His Efavirenz study integrates concerns from other disciplines, such as Atazanavir and Ritonavir.
The concepts of his Acquired immunodeficiency syndrome study are interwoven with issues in Life expectancy, Quality-adjusted life year, Psychiatry and Disease.
His most cited work include:
- Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia (1792 citations)
- The major genetic determinants of HIV-1 control affect HLA class I peptide presentation (910 citations)
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy (605 citations)
What are the main themes of his work throughout his whole career to date?
Paul E. Sax spends much of his time researching Internal medicine, Acquired immunodeficiency syndrome, Virology, Immunology and Antiretroviral therapy.
His Internal medicine research includes themes of Efavirenz, Ritonavir, Oncology and Emtricitabine.
His Ritonavir study incorporates themes from Darunavir, Atazanavir and Pharmacology.
His Emtricitabine study combines topics in areas such as Gastroenterology, Abacavir/Lamivudine and Tenofovir alafenamide.
His Acquired immunodeficiency syndrome research includes elements of Disease and Family medicine.
His Antiretroviral therapy research incorporates themes from Pediatrics and Intensive care medicine.
He most often published in these fields:
- Internal medicine (34.70%)
- Acquired immunodeficiency syndrome (19.24%)
- Virology (14.67%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (34.70%)
- Dolutegravir (5.21%)
- Emtricitabine (7.89%)
In recent papers he was focusing on the following fields of study:
Paul E. Sax mainly investigates Internal medicine, Dolutegravir, Emtricitabine, Clinical trial and Regimen.
Paul E. Sax combines subjects such as Gastroenterology, Lamivudine and Acquired immunodeficiency syndrome with his study of Internal medicine.
His studies in Dolutegravir integrate themes in fields like Integrase inhibitor, Pharmacotherapy, Drug resistance and Virology.
His research in Emtricitabine intersects with topics in Efavirenz, Elvitegravir, Tenofovir alafenamide and Coinfection.
His work investigates the relationship between Clinical trial and topics such as Viral load that intersect with problems in Viremia and Viral suppression.
His Life expectancy research focuses on Mean age and how it connects with Immunology.
Between 2015 and 2021, his most popular works were:
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel (414 citations)
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel (310 citations)
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial (127 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Acquired immunodeficiency syndrome
- Disease
Paul E. Sax mainly investigates Internal medicine, Dolutegravir, Regimen, Randomized controlled trial and Emtricitabine.
His work deals with themes such as Gastroenterology, Darunavir, Oncology and Ritonavir, which intersect with Internal medicine.
His Dolutegravir research is multidisciplinary, relying on both Integrase inhibitor and Viral load.
The Regimen study combines topics in areas such as Cohort study, Stroke, Clinical endpoint, Disease and Atazanavir.
His research in Randomized controlled trial focuses on subjects like Lamivudine, which are connected to Clinical trial and Pediatrics.
His research investigates the connection with Emtricitabine and areas like Tenofovir alafenamide which intersect with concerns in Bictegravir, Pharmacology, Cobicistat, Pre-exposure prophylaxis and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
